Acyl-CoA oxidase deficiency

Lore & Background

Acyl-CoA oxidase deficiency's symptoms begin at birth, and most affected newborns do not survive past early childhood. Affected individuals can be born with hypotonia, seizures, and dysmorphic features, such as widely spaced eyes, a low nasal bridge and low set ears. Polydactyly and hepatomegaly have also been described. Most babies will learn to walk and begin speaking, before experiencing a rapid decline in motor function between the ages of 1 and 3. As the person ages, and the condition worsens, they begin to experience exaggerated reflexes (hyperreflexia), more severe and frequent seizures, and gradual loss of vision and hearing.

Reader's Guide

Acyl-CoA oxidase deficiency is an extremely rare condition that highlights the critical role of peroxisomal enzymes in nervous system health. The disorder is caused by biallelic pathogenic variants in ACOX1, leading to defective breakdown of very long chain fatty acids. Their accumulation triggers inflammation and demyelination, resulting in leukodystrophy and progressive neurological decline. Diagnosis can be made prenatally via amniotic fluid analysis or after birth through blood tests for VLCFA levels and enzyme activity, though misdiagnosis with similar conditions such as Usher syndrome or neonatal adrenoleukodystrophy is possible. There is no cure; treatment is supportive, using pharmacologic agents for muscle tone and seizures, and physical therapy to improve movement. The condition's rapid progression and early lethality underscore the need for early detection and research into therapies targeting VLCFA accumulation.

Did You Know?

• Acyl-CoA oxidase deficiency is caused by pathogenic variants in the ACOX1 gene.
• Most affected newborns do not survive past early childhood, with a life expectancy of 5 years.
• Symptoms include hypotonia, seizures, dysmorphic features, polydactyly, and hepatomegaly.
• The disorder may be misdiagnosed as Usher syndrome or neonatal adrenoleukodystrophy.

The Molecular Cascade Behind Neurodegeneration

Acyl-CoA oxidase deficiency traces its origins to a single gene, ACOX1, which provides instructions for building an enzyme known as peroxisomal straight-chain acyl-CoA oxidase. Under normal circumstances, this enzyme handles the critical task of breaking down very long chain fatty acids, or VLCFAs, within the cell. When pathogenic variants disrupt the enzyme's function, that metabolic pathway stalls, and VLCFAs begin to pile up in tissues. The precise mechanism by which this accumulation translates into neurological damage is still not fully understood, but current research points to an inflammatory response within the nervous system. That inflammation, in turn, triggers demyelination—the stripping away of the protective myelin sheath that insulates nerve fibers. The resulting loss of white matter, a condition termed leukodystrophy, affects both the brain and the spinal cord. It is this progressive destruction of myelinated tissue that ultimately drives the severe neurological abnormalities seen in affected individuals, setting the stage for the rapid functional decline that characterizes the disease.

From Birth to Rapid Decline: The Clinical Journey

The earliest signs of ACOX1 deficiency are present from the moment of birth, though they may initially appear deceptively mild. Newborns typically display profound hypotonia, a near-complete absence of expected neonatal reflexes, and episodes of seizures. Distinctive facial features—widely spaced eyes, a flattened nasal bridge, ears set low on the head, and an unusually large forehead—often raise early clinical suspicion. Some infants also present with polydactyly or an enlarged liver. For a brief window, affected children may achieve milestones such as walking and speaking, creating a fragile sense of normalcy. Between roughly one and three years of age, however, a swift and devastating deterioration in motor abilities sets in, driven by ongoing demyelination and nerve damage. As the condition advances, reflexes become exaggerated, seizures grow more frequent and harder to control, and the child gradually loses the ability to see, hear, and respond to visual or physical stimuli. The life expectancy for an individual carrying this diagnosis is approximately five years, and most affected newborns do not survive beyond early childhood.

Inheritance and Rarity

Acyl-CoA oxidase deficiency follows an autosomal recessive inheritance pattern, meaning a child must inherit two pathogenic variants in the ACOX1 gene—one from each parent—to develop the condition. Parents who carry a single altered copy are typically unaffected but can pass the variant to their offspring. Because both alleles must be disrupted, the disorder is exceedingly rare, and many families encounter it for the very first time with the birth of an affected child. The ACOX1 gene sits within the peroxisomal pathway and is dedicated to producing the enzyme that metabolizes very long chain fatty acids. When both copies carry damaging mutations, the enzyme either functions poorly or is absent altogether, halting VLCFA degradation. Although the genetic basis is well established, the downstream biological steps that convert a metabolic block into progressive neurological injury remain an active area of investigation. Researchers believe the toxic accumulation of VLCFAs provokes an inflammatory cascade in the central nervous system, but the full sequence of events from molecular defect to clinical leukodystrophy has yet to be mapped in complete detail.

Diagnosis and the Limits of Treatment

Because ACOX1 deficiency is so uncommon, affected infants are frequently misdiagnosed as having other conditions, including Usher syndrome or neonatal adrenoleukodystrophy, which can delay definitive identification. Prenatal diagnosis is possible when a family's specific variants are known, using molecular testing on amniotic fluid or by measuring abnormally elevated VLCFA levels and reduced or absent enzyme activity in cultured fibroblasts. After birth, clinicians can assess serum VLCFA concentrations and acyl-CoA oxidase activity from a blood sample, and confirm the diagnosis through sequence or copy-number analysis of the ACOX1 gene. Treatment, however, remains purely supportive. No cure exists. Management focuses on alleviating individual symptoms: pharmacologic agents are prescribed to ease dystonia and modulate abnormal neurological signaling to muscles, while physical therapy aims to preserve whatever movement and function remain. For children whose seizures prove refractory to medication, surgical interventions are also available as an additional option.